B-CELL NON HODGKIN LYMPHOMA

This study tests a new type of immune cell therapy (CAR-T) for children and teens whose B-cell leukemia or lymphoma has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to target and kill cancer cells. The goal is to see…

This early-phase study tests a new treatment made from cord blood cells that are specially trained to find and attack B-cell lymphoma. The therapy, called IL-10/IL-15 CD19-CAR NK, is given to people whose lymphoma has not responded to or has returned after standard treatments. Th…

This early-phase study tests an experimental drug called SAR448501 in about 96 adults with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has not responded to or has returned after at least two prior treatments. The main goals are to check the drug's safety and find th…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The trial includes up to 49 participants,…

This early-phase study tests a new CAR-T cell treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The main goals are to find a safe dose and see how well the treatment works. About 27 adults aged 18-75 will…

This study is testing a new drug called AZD0486, either by itself or with other cancer treatments, in people with certain types of blood cancers like chronic lymphocytic leukemia and lymphoma. The main goals are to check if the drug is safe and to find the best dose. About 408 pa…

This study is for people with B-cell lymphoma that has come back or not responded to treatment. It combines a stem cell transplant with a special immune cell therapy called CD19 CAR-T. The goal is to see if this approach can make the cancer disappear and keep it away. About 16 pe…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to seek out and destroy cancer cells while sparing healthy ones. The study aims to fin…

This early-stage study tests a new drug called AZD0486 in about 227 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell and follicular lymphoma. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals…

This study tests a new kind of CAR T-cell therapy for adults with certain blood cancers (B-cell lymphoma or chronic lymphocytic leukemia) that have come back or not responded to treatment. The therapy uses a patient's own immune cells that are specially modified to be more energe…

This early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or recurrent B-cell lymphoma will receive the treatme…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This study tests new drugs for children and teens with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. Current treatments cure only about 30% of these patients and have harsh side effects. The trial will give participants one of several new medicines…

This study is for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are testing a drug called loncastuximab tesirine combined with other anti-cancer drugs to find the safest dose and see if it shrinks tumors. About 200 part…

This study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 adults with untreated or minimally treated disease will receive the combination. The goal is to improve c…

This study tests an experimental drug called AZD4512, alone or with other cancer drugs, in adults with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best…

This study tests a new drug called surovatamig in 240 adults with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or not improved after at least two prior treatments. The drug is given alone to see if it can shrink tumors and how safe it is. The trial is op…

This early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells. It is for people with certain types of blood cancers (like lymphoma or leukemia) that have returned or stopped respond…

This study tests whether a thorough health check (geriatric assessment) before CAR-T therapy can guide personalized support—like physical therapy, nutrition advice, and mental exercises—to help adults aged 60 and older recover faster. Participants have B-cell non-Hodgkin lymphoma…

This study follows about 40 people who received a Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, overall health, and any return of cancer over the long term. The goal is to better understand the lasting safety and effects of this treatment…